Du forlater nå GSKs nettsider

Denne lenken tar deg til en nettside som ikke tilhører GSK. GSK er ikke ansvarlig for, går ikke god for og aksepterer intet ansvar for informasjon eller meninger på nettsteder til tredjeparter



Personalized treatment in COPD - Symptomatic patients

GSK Professor Paul Jones held a highly interesting lecture about “An approach to personalized treatment in COPD” on March 30th at Karolinska University Hospital in Stockholm. This webinar is a mix of presentations discussing the need for personalized COPD treatment and addressing the answers to key questions regarding COPD treatment.

This webinar content is intended for healthcare professionals. Content includes product information.


Prof Jones - Two main types of COPD patients

Prof Jones - Underestimation of severity of COPD by patients and clinicians (part I)

Prof Jones - Underestimation of severity of COPD by patients and clinicians (Part II)

Prof Jones - COPD treatment aims

Prof Jones - Monobronchodilation – many patients stay still symptomatic

Prof Jones - Anoro efficacy data

Prof Jones - Dual bronchodilation works efficiently even in poor responders to monobronchodilators

Prof Jones - Whom to give dual bronchodilator as IMT

Event speaker information

Prof Paul Jones

Emeritus Professor of Respiratory Medicine at St George’s, University of London in London, UK and Global Medical Expert within GSK

Prof Jones developed the St George’s Respiratory Questionnaire (SGRQ), the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) and the EXACT exacerbation diary card. His current research concerns the effect of COPD on cognitive function and brain structure.
He is Joint Editor of the Clinical Respiratory Journal , an Associate Editor of the Journal of the COPD Foundation and on the Editorial Board of Chest. He sat on the British Asthma Guidelines executive group for several years and was a member of the Global Initiative for Chronic Obstructive Disease (GOLD) Science Committee and the GOLD Board of Directors until he joined GSK.